July 22, 2024: NCHR’s letter for the record for the House hearing: “The Fiscal Year 2025 Consumer Product Safety Commission Budget” describes the accomplishments of the CPSC and urges Congress to support CPSC’s life-saving work evaluating consumer products, especially those for children, in order to keep all of us safe.
Read More »On Health Policy
NCHR Signed On to Letter Urging Greater Appropriations for the Consumer Product Safety Commission
NCHR and other non-profit organizations sent a letter urging increased FY 2025 appropriations for the Consumer Product Safety Commission. CPSC funding should not be subject to cuts or restrictions that would further undermine its ability to protect the public from hazardous consumer products.
Read More »NCHR Testimony at the FDA Listening Session on Advisory Committee Meetings
June 13, 2024: NCHR testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs and the ability of individuals with prior financial ties to industry to serve on these committees.
Read More »The Patient, Consumer, and Public Health Coalition Testified at an FDA Listening Session on Advisory Committees
June 13, 2024: The Patient, Consumer, and Public Health coalition testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs, the inherent conflicts of interests of committee members, and inadequate training provided to appointees.
Read More »NCHR’s Public Comment on Early Alzheimer’s Disease: Developing Drugs for Treatment; Draft Guidance for Industry
June 10, 2024: NCHR disagrees with assumptions made in FDA guidance aimed at developing drugs for treatment of early stages of Alzheimer’s dementia.
Read More »